EEG-based Personalized Transcranial Magnetic Stimulation (eTMS) to Treat Post-Traumatic Stress Disorder
Launched by WAVE NEUROSCIENCE · Mar 17, 2025
Trial Information
Current as of May 24, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is exploring a new treatment called EEG-based Transcranial Magnetic Stimulation (eTMS) for people with Post-Traumatic Stress Disorder (PTSD). The study aims to recruit 110 participants, specifically U.S. military veterans and first responders like firefighters and police officers. To be eligible, participants must be between 22 and 65 years old, have been diagnosed with PTSD for at least six months, and meet certain scoring criteria. It's important that they also agree to participate in the study by signing a consent form.
If you decide to participate, you can expect to have an EEG recording to help determine the best treatment approach. You will then attend 15 office visits over 21 to 28 days, during which you will receive two treatment sessions each time. This trial is currently recruiting, and it aims to provide new hope for those struggling with PTSD. Just a reminder, some people may not be eligible, especially if they have certain medical conditions or a history of specific treatments.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Willing and able to consent to participate in the study via signed Informed Consent
- • Age 22 - 65 years
- • Diagnosis of PTSD according to DSM-5 criteria via the Clinician-Administered PTSD Scale (CAPS).
- • Onset of symptoms meeting the DSM-5 criteria for PTSD symptoms persisting for a minimum of 6 months prior to the Screening Visit
- • Veterans Administration PCL-5 cut point score of 31 or above
- • Positive identification as either a Veteran, or First Responder (e.g., emergency medical service provider, firefighter, or any other emergency response personnel)
- Exclusion Criteria:
- • Uncontrolled medical, psychological or neurological condition
- • Pregnant, or female unwilling to use effective birth control during the course of the trial
- • Metal objects in the head
- • Past exposure to metal fragments, permanent piercings, and/or other possible metal sources in the head and neck
- • Current participation in any interventional research protocol
- • History of any type of Electroconvulsive Therapy (ECT) or repetitive Transcranial Magnetic Stimulation (rTMS)
- • History of stroke or intracranial lesion or increased intracranial pressure
- • History of epilepsy of seizure
- • Family history of epilepsy or seizure in 1st degree relative
- • An elevated risk of suicide or violence to others
About Wave Neuroscience
Wave Neuroscience is a pioneering clinical trial sponsor specializing in the development of innovative therapies for neurological and psychiatric disorders. Committed to advancing brain health, the organization leverages cutting-edge research and technology to explore novel treatment modalities, including neuromodulation and neurostimulation techniques. With a focus on rigorous clinical evaluation and patient-centered approaches, Wave Neuroscience aims to transform the landscape of mental health care and improve outcomes for individuals affected by complex neurological conditions. Their collaborative efforts with leading researchers and institutions underscore their dedication to driving scientific progress and enhancing therapeutic options.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Dayton, Ohio, United States
Pickerington, Ohio, United States
Patients applied
Trial Officials
Bill Phillips, PhD
Principal Investigator
Wave Neuroscience, Inc.
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported